Jazz Pharmaceuticals PLC Form 4 insider transactions

Jazz Pharmaceuticals plc Director Bruce C. Cozadd sold 6,000 ordinary shares in pre-planned transactions on September 2, 2025.

Jazz Pharmaceuticals director Kenneth W. O'Keefe reported the acquisition of restricted stock units and the sale of shares to cover tax obligations.

Jazz Pharmaceuticals plc director Jennifer E. Cook received a grant of 3,507 restricted stock units and sold 1,805 shares to cover tax obligations from a prior RSU vesting.

A Jazz Pharmaceuticals director acquired restricted stock units and sold shares to cover tax obligations from a prior vesting event.

A Jazz Pharmaceuticals director acquired new restricted stock units and sold shares to cover tax obligations from prior vesting.

A Jazz Pharmaceuticals director reported acquiring restricted stock units and selling shares to cover tax obligations from prior equity awards.

A Jazz Pharmaceuticals director acquired new restricted stock units and sold shares to cover tax obligations from a prior vesting.

Jazz Pharmaceuticals plc Director Anne O'Riordan reported the acquisition of restricted stock units and the sale of shares to cover tax obligations.

Jazz Pharmaceuticals plc Director Norbert G. Riedel reported the grant of restricted stock units and a subsequent sale of shares to cover tax obligations.

A Jazz Pharmaceuticals director reported the acquisition of restricted stock units and the sale of shares to cover tax obligations.

A Jazz Pharmaceuticals plc director reported acquiring restricted stock units and selling shares to cover tax obligations.

Jazz Pharmaceuticals plc Director Seamus Mulligan reported the acquisition of 3,507 restricted stock units.

Jazz Pharmaceuticals plc's President and CEO, Renee D. Gala, reported the acquisition of 18,808 ordinary shares through a restricted stock unit grant and 166 shares via an employee stock purchase plan.

Jazz Pharmaceuticals' Chief Commercial Officer, Samantha Pearce, reported changes in her beneficial ownership, including shares withheld for tax obligations and an acquisition via an employee stock plan.

Jazz Pharmaceuticals plc CEO Bruce C. Cozadd sold 1,000 ordinary shares for $113.21 each on August 1, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals plc's Chairman and CEO, Bruce C. Cozadd, reported the sale of 1,000 ordinary shares through a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals plc's Chairman and CEO, Bruce C. Cozadd, reported the sale of 1,000 ordinary shares through a pre-arranged 10b5-1 trading plan in early June, while also acquiring 166 shares via an employee stock purchase plan.

Director Seamus Mulligan reports purchasing Jazz Pharmaceuticals shares through Nerano Pharma Limited in multiple transactions.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, sold a portion of his ordinary shares under a pre-arranged Rule 10b5-1 trading plan.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, sold 1,500 ordinary shares at $123.75 per share on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Robert Iannone, EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals, reported the sale of 2,403 ordinary shares on March 10, 2025.

Mary Elizabeth Henderson, SVP of Technical Operations at Jazz Pharmaceuticals, sold 698 ordinary shares to satisfy tax obligations from vesting restricted stock units.

Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, reports the sale of ordinary shares to cover tax obligations and other transactions.

Samantha Pearce, EVP and Chief Commercial Officer of Jazz Pharmaceuticals, sold 1,905 ordinary shares to cover tax obligations arising from vesting restricted stock units.

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, disposed of 4,088 ordinary shares to satisfy tax obligations arising from vesting restricted stock units.

Philip L. Johnson, EVP & Chief Financial Officer of Jazz Pharmaceuticals plc, sold 1,149 ordinary shares on March 5, 2025, to satisfy tax obligations arising from vesting restricted stock units.

Robert Iannone, EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals, sold shares of the company's stock on March 5th and 7th, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Renee D Gala, President & COO of Jazz Pharmaceuticals, sold 5,704 ordinary shares on March 5, 2025, to cover tax obligations arising from the vesting of restricted stock units.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, disposed of 22,251 ordinary shares to satisfy tax obligations arising from the vesting of restricted stock units.

Robert Iannone, EVP, G R&D and CMO of Jazz Pharmaceuticals, reports acquisition of restricted stock units.